In vitro Models of the Blood–Brain Barrier: Tools in Translational Medicine
Open Access
- 15 February 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Medical Technology
- Vol. 2, 623950
- https://doi.org/10.3389/fmedt.2020.623950
Abstract
Medical progress has historically depended on scientific discoveries. Until recently, science was driven by technological advancements that, once translated to the clinic, fostered new treatments and interventions. More recently, technology-driven medical progress has often outpaced laboratory research. For example, intravascular devices, pacemakers for the heart and brain, spinal cord stimulators, and surgical robots are used routinely to treat a variety of diseases. The rapid expansion of science into ever more advanced molecular and genetic mechanisms of disease has often distanced laboratory-based research from day-to-day clinical realities that remain based on evidence and outcomes. A recognized reason for this hiatus is the lack of laboratory tools that recapitulate the clinical reality faced by physicians and surgeons. To overcome this, the NIH and FDA have in the recent past joined forces to support the development of a “human-on-a-chip” that will allow research scientists to perform experiments on a realistic replica when testing the effectiveness of novel experimental therapies. The development of a “human-on-a-chip” rests on the capacity to grow in vitro various organs-on-a-chip, connected with appropriate vascular supplies and nerves, and our ability to measure and perform experiments on these virtually invisible organs. One of the tissue structures to be scaled down on a chip is the human blood–brain barrier. This review gives a historical perspective on in vitro models of the BBB and summarizes the most recent 3D models that attempt to fill the gap between research modeling and patient care. We also present a summary of how these in vitro models of the BBB can be applied to study human brain diseases and their treatments. We have chosen NeuroAIDS, COVID-19, multiple sclerosis, and Alzheimer's disease as examples of in vitro model application to neurological disorders. Major insight pertaining to these illnesses as a consequence of more profound understanding of the BBB can reveal new avenues for the development of diagnostics, more efficient therapies, and definitive clarity of disease etiology and pathological progression.Keywords
This publication has 147 references indexed in Scilit:
- Expression and functional relevance of UGT1A4 in a cohort of human drug‐resistant epileptic brainsEpilepsia, 2013
- In Vitro Blood–Brain Barrier Models: Current and Perspective TechnologiesJournal of Pharmaceutical Sciences, 2012
- The role of shear stress in Blood-Brain Barrier endothelial physiologyBMC Neuroscience, 2011
- Apolipoprotein E Regulates the Integrity of Tight Junctions in an Isoform-dependent Manner in an in Vitro Blood-Brain Barrier ModelJournal of Biological Chemistry, 2011
- Cellular localization and functional significance of CYP3A4 in the human epileptic brainEpilepsia, 2011
- A Dynamic in vitro BBB Model for the Study of Immune Cell Trafficking into the Central Nervous SystemJournal of Cerebral Blood Flow & Metabolism, 2010
- Pattern of P450 expression at the human blood–brain barrier: Roles of epileptic condition and laminar flowEpilepsia, 2010
- Tobacco smoke: A critical etiological factor for vascular impairment at the blood–brain barrierBrain Research, 2009
- Blood–brain barrier damage and brain penetration of antiepileptic drugs: Role of serum proteins and brain edemaEpilepsia, 2009
- PKCη regulates occludin phosphorylation and epithelial tight junction integrityProceedings of the National Academy of Sciences of the United States of America, 2009